Clinical features, treatment, and outcomes of anti-PD-1/PD-L1 immune checkpoint inhibitors induced dermatomyositis
During anti-PD-1/PD-L1 therapy, closely monitor patients' cutaneous and muscular symptoms to detect DM early. For diagnosed DM patients, implement timely interventions according to symptom severity.
Authors
- Fengrui Yang (ORCID: https://orcid.org/0000-0002-8558-1419)
- Xia Zd
- Jian Xiao (ORCID: https://orcid.org/0000-0003-2761-1779)
- Min Fang (ORCID: https://orcid.org/0000-0002-7910-9169)
- Siwei Liao
Institutions
- Central South University (CN)
- Changsha Medical University (CN)
- Hunan Normal University (CN)
- National Clinical Research (US)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Immunopharmacology and Immunotoxicology
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1080/08923973.2026.2638325
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00